Schizophrenia and increased risks of cardiovascular disease
2005/12/01 by Charles H. Hennekens, Alissa R. Hennekens, Danielle Hollar +1 · 1,074 citations
Medicine · Neuroscience · Psychology · #Absolute risk reduction #Environmental health #Healthcare Decision-Making and Restraints #Internal medicine #Life expectancy #Medicine #Pediatrics #Population #Psychiatry #Risk factor #Schizophrenia (object-oriented programming) #Schizophrenia research and treatment #Tryptophan and brain disorders
paper · doi:10.1016/j.ahj.2005.02.007
published in American Heart Journal 150(6), 1115-1121 (Elsevier BV)
openalex publication_date 2005/12/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
Cited by
- Centrality statistics of symptom networks of schizophrenia: a systematic review
- Unhealthy lifestyle in early psychoses: The role of life stress and the hypothalamic–pituitary–adrenal axis
- Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
- Evaluation of autonomic nervous system by salivary alpha-amylase level and heart rate variability in patients with schizophrenia
- What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?
- Individual Dietetic Consultations in First Episode Psychosis: A Novel Intervention to Reduce Cardiometabolic Risk
- Differential pattern of heart rate variability in patients with schizophrenia
- Cardiovascular disease in patients with schizophrenia
- Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
- Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
- Treating schizophrenia during menopause
- The evolution of drug development in schizophrenia: past issues and future opportunities. [europepmc]
- Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. [europepmc]
- Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. [europepmc]
- Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. [europepmc]
- Cigarette smoking and mortality risk in people with schizophrenia. [europepmc]
- Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. [europepmc]
- Testing the hypothesis of accelerated cerebral white matter aging in schizophrenia and major depression. [europepmc]
- Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. [europepmc]
- Microvascular abnormality in schizophrenia as shown by retinal imaging. [europepmc]
- The genomics of schizophrenia: update and implications. [europepmc]
- Comorbidity profile and healthcare utilization in elderly patients with serious mental illnesses. [europepmc]
- Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. [europepmc]
- Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. [europepmc]
- Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. [europepmc]
- Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. [europepmc]
- Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. [europepmc]
- Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia? [europepmc]
- A widening longevity gap between people with schizophrenia and general population: A literature review and call for action. [europepmc]
- Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. [europepmc]
- Stress, Telomeres, and Psychopathology: Toward a Deeper Understanding of a Triad of Early Aging. [europepmc]
- Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. [europepmc]
- Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. [europepmc]
- Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. [europepmc]
- Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects. [europepmc]
- Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. [europepmc]